Curated news and analysis on clinical trials, drug approvals, and medical research.
Rhythm reported Q1 2026 IMCIVREE revenue of $60.1 million and said more than 150 patient start forms were received after U.S. approval in acquired hypothalamic obesity. The company also cited European authorization and a Japanese application under review.
BrightGene Bio-Medical reported Phase III data for BGM0504 showing 19.3% mean weight reduction and improvements in blood pressure, lipids and uric acid. The data highlighted GIP as a key variable in broader metabolic management.
A review in Genes & Diseases says robust non-clinical safety assessment is critical for CRISPR-based gene therapies. It highlights genotoxic, delivery, and immunological risks and recommends risk-based development programs.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
A large analysis of 131,821 health professionals found that two to three cups of caffeinated coffee a day were linked to a 19 percent lower dementia risk. One daily cup of caffeinated tea was linked to a 14 percent lower risk.
A 2026 review outlines the shift in solid organ transplantation from broad immunosuppression to Treg-based active tolerance. It covers polyclonal Tregs, CAR-Tregs and CRISPR-edited off-the-shelf products.
Recent studies in retinitis pigmentosa showed mixed results for gene and optogenetic therapies. UGX-201 and MCO-010 were associated with visual acuity improvements, while AAV8.hPDE6A showed no significant functional gains at 1 year.
Early clinical studies highlighted nonhormonal male contraception candidates YCT-529 and ADAM. YCT-529 showed favorable phase 1a safety, while ADAM reported mild transient effects and durability up to 24 months.
Hearings in Benjamin Netanyahu’s criminal trial were canceled this week after the death of a close family member of one presiding judge. The case remains in cross-examination in Case 4000, and Netanyahu is not expected back on the stand before next week.
A pooled analysis of five randomized trials found intranasal esketamine improved MADRS scores in adults with TRD in both sexes. Females showed greater improvement and higher odds of treatment-response toward trial end.
Research found women undergoing breast reconstruction after mastectomy have goals extending beyond physical restoration. Newer nerve-preserving techniques aim to restore chest and nipple sensation but are still being studied.
A Nature Communications study reported that STING agonist 8803 inhibited tumor growth in human meningioma samples and reduced tumor volume and mortality in mouse models. Researchers found the STING pathway is expressed in both meningioma tumor cells and immune cells in the tumor microenvironment.
The FDA has accepted for review a supplemental application for taletrectinib in advanced ROS1-positive NSCLC, with a PDUFA date of January 4, 2027. Updated TRUST-I and TRUST-2 data showed high response rates, durable responses and no new safety signals.
NIH said it will no longer classify BESH studies as clinical trials for grant applications due on or after May 25, 2026. The change removes ClinicalTrials.gov registration and reporting requirements for those studies.
LIB Therapeutics launched Lerochol in the United States after FDA approval for lowering LDL-C in adults with hypercholesterolemia, including HeFH. The once-monthly PCSK9 inhibitor is available with a $199-per-month cash-pay option.
A phase 1 study found MP0317, a FAP-targeting CD40 agonist, showed tumor-localized CD40 activation, a favorable safety profile, and immune remodeling in advanced solid tumors.
The S&P 500 has swung to a loss for the year as volatility, geopolitical strains and profit-taking weigh on large-cap stocks. SanDisk, Venture Global and Moderna were among the top gainers.
Studies found gut microbiome changes linked to Parkinson’s risk before symptoms and hair mineral differences in diagnosed patients. Both findings need larger follow-up studies.
Western Australia will invest more than $5 million in the 2026-27 State Budget to support regional air routes. The package includes $3.8 million for the Inter-Regional Flight Network and more than $1.3 million for two Kimberley services.
DX-104, a next-generation gOMV vaccine candidate for MenB, is planned for trials in China and Australia. The process scaled to 100 L, reached 98% purity, and is projected to yield over 1 million doses per batch.
